	US 11,655,308 B2
	HM-3 fusion protein and application thereof
Ruijing Huang, Shanghai (CN); Baoqing Fan, Shanghai (CN); Jian Li, Shanghai (CN); Xiaohui Ma, Shanghai (CN); Yibo Wang, Shanghai (CN); Lihua Zhang, Tianjin (CN); Xiaodan Cao, Shanghai (CN); Wenlei Li, Shanghai (CN); Pengyin Wang, Shanghai (CN); and Yan Chen, Shanghai (CN)
Assigned to TASLY BIOPHARMACEUTICALS CO., LTD., Shanghai (CN)
Appl. No. 16/768,619
Filed by TASLY BIOPHARMACEUTICALS CO., LTD., Shanghai (CN)
PCT Filed Nov. 23, 2018, PCT No. PCT/CN2018/117188 § 371(c)(1), (2) Date Sep. 23, 2020, PCT Pub. No. WO2019/109819, PCT Pub. Date Jun. 13, 2019.
Claims priority of application No. 201711273473.9 (CN), filed on Dec. 6, 2017.
Prior Publication US 2021/0009717 A1, Jan. 14, 2021
Int. Cl. C07K 19/00 (2006.01); A61K 9/00 (2006.01); A61K 38/16 (2006.01)

CPC C07K 19/00 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0053 (2013.01); A61K 38/16 (2013.01); C07K 2319/30 (2013.01)]

11 Claims

1. A fusion protein, formed by linking an HM-3 and IgG-Fc, wherein the HM-3 is a polypeptide linked by a Linker to an N-terminus and/or a C-terminus of the IgG-Fc, and

wherein the fusion protein is selected from the group consisting of

TSL-1, which is HM-3-(GGGGS)₃-IgG2-Fc (SEQ ID NO:9);

TSL-2, which is HM-3-(GGGGS)₃-mIgG4-Fc (SEQ ID NO:10);

TSL-3, which is IgG2-Fc-(GGGGS)₃-HM-3 (SEQ ID NO:11);

TSL-4, which is mIgG4-Fc-(GGGGS)₃-HM-3 (SEQ ID NO:12);

TSL-13, which is HM-3-(GGGGS)₃-mIgG4-Fc-(GGGGS)₃-HM-3 (SEQ ID NO:15);

TSL-15, which is mIgG4-Fc-G5-HM-3-G8-HM-3 (SEQ ID NO:17);

TSL-16, which is HyFc-(GGGGS)₃-HM-3 (SEQ ID NO:18);

TSL-17, which is mIgG4-Fc-A(EAAAK)₄A-HM-3 (SEQ ID NO:19); and

TSL-18, which is mIgG4-Fc-(AP)₉-HM-3 (SEQ ID NO:20).